ASP Isotopes
$6.56
+0.0050 (0.08%)
A leader in isotope enrichment technology for the medical, green energy and industrial sectors
Join the ASP Isotopes Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow ASP Isotopes as new developments unfold.
Company Overview
ASP Isotopes is an advanced materials company transitioning from development into commercial production of high-value isotopes and critical gases. The Company employs its proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment technology to produce and commercialize isotopes essential to healthcare, semiconductors, and clean energy. ASPI is progressing toward initial commercial shipments across Silicon-28, Carbon-14, and Ytterbium-176 in 2026, supported by multiple operating enrichment facilities in South Africa. Through strategic partnerships, including TerraPower, ASPI is advancing High Assay Low Enriched Uranium (HALEU) supply for next-generation nuclear reactors, while its joint venture with Fermi America provides a U.S. base for stable isotope and nuclear fuel production.
Following the completed acquisition of Renergen, ASPI has expanded into helium and natural gas production, with Phase 1 drilling at the Virginia Gas Project completed ahead of schedule and nameplate capacity targeted in the third quarter of 2026. In parallel, the Company is advancing its Quantum Leap Energy subsidiary to develop next-generation nuclear fuel technologies. Together, these initiatives position ASPI as a vertically integrated global provider of critical isotopes and materials serving high-growth markets including semiconductors, quantum computing, and clean energy.
Value Proposition
ASPI is emerging as a category-defining platform in the global critical materials and isotope supply chain, transitioning from development to early commercialization with multiple revenue streams expected to scale in 2026. With several operating enrichment facilities in South Africa, the Company is advancing toward initial commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176—each supporting high-value applications across semiconductors, nuclear medicine, and clean energy. These milestones validate ASPI’s proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment technologies and demonstrate their scalability into repeatable commercial production.
The Company’s strategic partnerships and industrial relationships provide uncommon market access and long-duration visibility. Definitive agreements with TerraPower include secured financing and a multi-year HALEU supply framework, positioning ASPI as a cornerstone supplier to next-generation nuclear reactor deployments. The joint venture with Fermi America establishes a U.S. footprint for stable isotope and nuclear fuel production at a strategically pre-qualified site, aligning ASPI with the buildout of advanced energy and data infrastructure in the United States. In parallel, Quantum Leap Energy is advancing international expansion and next-generation enrichment capabilities, including a strategic collaboration with the University of Bristol to develop a dedicated laser-based research facility supporting lithium isotope production and future nuclear fuel applications.
The acquisition of Renergen meaningfully expands ASPI’s addressable market and near-term cash flow potential. By integrating helium production and natural gas operations, ASPI has evolved into a vertically integrated critical materials provider spanning isotopes and electronic gases. Recent operational progress—including completion of Phase 1 drilling at the Virginia Gas Project approximately four months ahead of schedule and achievement of required flow rates—has materially reduced execution risk and increases confidence in reaching nameplate capacity in the third quarter of 2026. At the same time, global helium markets are experiencing supply disruption driven by geopolitical constraints impacting key producers, reinforcing the strategic value of new, reliable supply sources.
Looking ahead, ASPI is advancing additional Quantum Enrichment facilities targeting Nickel-64, Gadolinium-160, and Lithium-6/7—materials facing acute Western shortages and serving multi-billion-dollar end markets in radiotherapy, imaging, fusion, and advanced nuclear energy. In parallel, Quantum Leap Energy continues to progress regulatory engagement, technology development, and capital formation initiatives, including a planned future separation intended to unlock incremental shareholder value while sharpening ASPI’s strategic focus.
Supported by proven technology, visible execution milestones, and powerful geopolitical tailwinds favoring secure domestic supply of critical materials, ASPI represents one of the few independent platforms capable of serving multiple high-growth sectors at scale. For investors, the Company offers a differentiated risk-reward profile defined by a near-term transition to commercial revenues, multiple parallel growth vectors, and strategic positioning at the intersection of healthcare innovation, quantum computing, advanced nuclear energy, and electronic materials.
Investor Presentation
Investment Highlights
Game-changing strategic partnerships and agreements
- Signed definitive agreements with TerraPower (founded by Bill Gates) to finance and supply up to 150 MT of HALEU over 10 years, beginning 2028; supports Natrium SMR project.
- Entered joint venture with Fermi America (co-founded by former U.S. Energy Secretary Rick Perry) to build a HALEU enrichment facility at the 11GW HyperGrid campus in Texas, alongside a 100% ASPI-owned stable isotope production plant.
- Entered MOU with Necsa to co-develop nuclear fuel facilities at Pelindaba, South Africa.
- Quantum Leap Energy entered a strategic collaboration with the University of Bristol to design a next-generation laser enrichment research facility supporting lithium isotope production and future nuclear fuel applications.
- Strategic investment in IsoBio, Inc., advancing antibody-isotope conjugates (AICs™) for cancer therapy, supported by ASPI’s isotope supply chain.
Commercial production milestones achieved and accelerating
- Silicon-28: Commercial production commenced March 2025; customer shipments underway with first commercial deliveries targeted in 2026.
- Carbon-14 / Carbon-12: Enrichment underway with initial commercial shipments expected in 2026, supported by secured multi-year supply agreement.
- Ytterbium-176: Quantum Enrichment facility commissioned; targeting initial commercial shipments in 2026 following successful customer sampling.
- Multiple isotope platforms expected to reach first commercial shipments in 2026, marking ASPI’s transition to revenue scale across nuclear medicine and semiconductor applications.
- Three enrichment facilities now operational in South Africa, marking ASPI’s transition from R&D to revenue-generating operations.
Transformational acquisition expands ASPI into helium and critical gases
- Completed acquisition of Renergen, creating a vertically integrated critical materials company spanning isotopes, helium, and natural gas; expansion supported by up to $750 million of committed debt financing, including funding from the U.S. Development Finance Corporation (DFC), materially de-risking scale-up and growth.
- Phase 1 drilling at the Virginia Gas Project completed ~4 months ahead of schedule, achieving required flow rates and materially reducing execution risk ahead of production ramp.
- Helium Phase 1 nameplate capacity targeted for Q3 2026, with well performance exceeding prior expectations and remaining work largely engineering and tie-in related.
- Virginia Gas Project positions ASPI as a future global supplier of liquid helium, a strategically critical input for semiconductors, quantum computing, aerospace, and medical imaging.
Expanding pipeline and multiple value-creation levers
- Preparing construction of additional Quantum Enrichment facilities targeting Nickel-64, Gadolinium-160, and Lithium-6/7, addressing acute Western shortages across radiotherapy, imaging, fusion, and advanced nuclear applications.
- Quantum Leap Energy advancing regulatory engagement, U.S. and UK program development, and potential public listing, supporting long-term value realization and capital formation.
- Quantum Leap Energy advancing regulatory pathways in the UK for HALEU production and pursuing laser enrichment scale-up, with a planned future spinout to unlock shareholder value.
Massive market demand aligned with geopolitical tailwinds
- Global HALEU demand valued at $37B+ through 2037; ASPI engaged with multiple SMR developers and governments.
- Structural shortages of isotopes such as Silicon-28, Ytterbium-176, Nickel-64, and Lithium-6/7, historically dependent on Russia and China.
- Helium markets experiencing acute supply disruption due to geopolitical constraints impacting major producers (including Qatar), driving tightening supply and upward pricing pressure, while demand from semiconductors, AI infrastructure, and quantum technologies continues to increase.
Highly experienced leadership with execution track record
- Paul Mann (CEO/Chairman): former Soros, Highbridge, and Morgan Stanley; co-founder of ASPI.
- Deep technical bench across isotope enrichment, nuclear fuels, and industrial scale-up, complemented by newly integrated Renergen operating team.
Sign Up For ASPI Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
ASP Isotopes (ASPI) agreed to pay RedChip Companies, Inc., a $12,500 monthly cash fee and $50,000 of Rule 144 stock, deemed earned immediately after the IPO, beginning in August 2022, for 12 months of RedChip investor awareness services. ASPI also agreed to pay RedChip a $50,000 fee for a national TV ad campaign aired May 10 to May 24, 2024. As of September 2024, RedChip’s shares of ASPI are unrestricted and RedChip intends to sell all of its shares immediately and you may be buying as RedChip is selling. As of November 1, 2024, RedChip has sold all of its ASPI shares.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.